Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

Health Yuan and Lizhu Group, leading the transformation and innovation of the pharmaceutical industry, both rank among the top ten of the "Top 50" list.

Published Time:

2022-09-13

Author: Yuan Liang

Under the continuous influence of policies such as centralized procurement and dynamic medical insurance negotiations, the landscape of China's pharmaceutical industry is being restructured in the midst of accelerated innovation and transformation. Against the backdrop of the industry's rapid reshuffling, a large number of pharmaceutical companies have been eliminated or 'cleared out' due to their inability to adapt to the needs of the new era. Conversely, pharmaceutical companies with an innovative spirit and a knack for seizing opportunities in the industry's transformation are becoming industry leaders through their comprehensive strength and continuous innovation.

Recently, the "China Pharmaceutical Innovation and Upgrade Model 50" list was officially released. The aim of this list is to identify the most innovative and transformative pharmaceutical listed companies in China, uncover exemplary forces leading the innovation and transformation of China's pharmaceutical industry, and discover China's industrial experience in pharmaceutical innovation. Companies that made the list have demonstrated outstanding performance in industrial innovation, especially those at the top, who are beginning to take on the role of "leaders" in the new era of the industry. From the specific rankings, "Red Weekly" found that Health Yuan and Lizhu Group were ranked seventh and ninth respectively, both among the top ten, showing the characteristics of industry innovation "leaders".

Revenue and net profit are among the top in the industry

Comprehensive innovation strength is continuously demonstrated

According to publicly available information, the sample selected for this list includes 115 listed companies that, as of the end of 2021, had been listed on domestic and foreign stock exchanges for more than one year, and whose main business is generic drugs or a combination of generic and innovative businesses; A-share companies included in the Shenwan classification of Traditional Chinese Medicine and Biomedicine-Chemical Pharmaceuticals-Chemical Preparations; Hong Kong-listed pharmaceutical companies in the GICS industry classification of Health Care-Pharmaceuticals; and US-listed Chinese companies included in the US-Pharmaceuticals category.

Meanwhile, it is understood that the selection is based on the three dimensions of capital, profit, and R&D of the innovation and transformation analysis model. The capital dimension refers to the company's position and development potential in the industry, focusing on the company's development space and growth, with the main business revenue as the selected indicator. The profit dimension refers to the company's management level and ability, focusing on the company's profitability, with the return on net profit attributable to the parent company as the selected indicator. The R&D dimension refers to the company's investment, operation, and value-added capabilities in innovation and transformation, focusing on the company's R&D capabilities, with R&D investment as the selected indicator.

Among them, in terms of revenue, one of the three important dimensions of this list, the top five in 2021 were Fosun Pharma with revenue of 39 billion yuan, Shiyao Group with revenue of 27.9 billion yuan, China Biopharmaceutical with revenue of 26.9 billion yuan, Hengrui Medicine with revenue of 25.9 billion yuan, and Renfu Medicine with revenue of 20.4 billion yuan. Health Yuan and Lizhu Group, with revenues of 15.9 billion yuan and 12 billion yuan respectively, ranked seventh and tenth.

In terms of net profit attributable to the parent company, another important selection dimension of this list, the top five in 2021 were China Biopharmaceutical with a net profit of 16.6 billion yuan, Shiyao Group with a net profit of 5.7 billion yuan, Fosun Pharma with a net profit of 4.7 billion yuan, Hengrui Medicine with a net profit of 4.5 billion yuan, and KangZhe Pharmaceutical with a net profit of 3 billion yuan. Lizhu Group and Health Yuan, with net profits of 1.8 billion yuan and 1.3 billion yuan respectively, also ranked around tenth place.

This selection is based on the sum of the weighted scores of the three indicators: main business revenue, net profit, and R&D expenses. The weight of operating revenue and net profit accounts for 50%. In these two indicators, the performance rankings of Health Yuan and Lizhu Group are already among the top in the industry, and their comprehensive strength is becoming increasingly prominent.

Strong momentum for innovation and upgrading

R&D investment and revenue ratio are both among the top ten in the industry

According to the "2021 Annual Drug Review Report" released by the National Medical Products Administration, by the end of 2021, the CDE had accepted 11,700 applications for drug clinical registration, of which 1,886 were for innovative drugs, a year-on-year increase of 76.1%. 69 innovative drug marketing authorizations were approved, a year-on-year increase of 130%, involving 47 varieties. This fully demonstrates that domestic new drug listing applications are showing an explosive growth.

The success of industry innovation and transformation is inseparable from another key indicator in this selection—R&D expenses, which account for a full 50% of the weighting. This weighting shows that the amount of R&D investment has almost become a decisive factor in the success or failure of pharmaceutical companies' innovation and transformation.

According to observations, the top five in R&D expenses in the "Model 50" list in 2021 were Hengrui Medicine with 6.2 billion yuan, Fosun Pharma with 5 billion yuan, China Biopharmaceutical with 3.8 billion yuan, Shiyao Group with 3.4 billion yuan, and YuanDa Pharmaceutical with 2 billion yuan. Health Yuan and Lizhu Group ranked sixth and eighth with investments of 1.9 billion yuan and 1.5 billion yuan respectively.

From the perspective of the ratio of R&D investment to revenue, Health Yuan and Lizhu Group's R&D investment accounted for 12% and 13% of their revenue respectively, ranking among the top five on the list. Looking at the long-term trend, it becomes even clearer. Taking Health Yuan as an example, its R&D investment has increased significantly from 600 million yuan in 2016 to 1.9 billion yuan in 2021, a more than 300% increase in five years. Such large-scale investment and high-intensity R&D have given innovative comprehensive pharmaceutical companies such as Health Yuan and Lizhu Group the potential to become "dark horses." It is reported that the v-01 (recombinant novel coronavirus fusion protein vaccine) jointly developed by the company has been officially included in the emergency use of sequential booster immunization for novel coronavirus prevention, which is a strong testament to the company's successful innovation and upgrading. In the future, as the company continues to deepen its transformation into an innovative comprehensive pharmaceutical company, its upward space will further expand, and its growth attributes will undoubtedly become more prominent.

 

Disclaimer: This article is for reference only and does not constitute investment advice.

 

Source: Securities Market Red Weekly